Schedule a Consultation
(716) 839-3638
Xarelto for Deep Vein Thrombosis - rivaroxaban for DVT - and Buffalo Niagara Vein Treatment Center and Dr Karamanoukian
Friday, August 16, 2013



Acute venous thromboembolism is a common disorder with an annual incidence of 1 to 2 cases per 1000 persons in the general population.  Treatment with anticoagulants is effective in reducing the risk of recurrent disease, most notably increased in the first 6 to 12 months after the first episode of deep vein thrombosis.  The risk of recurrent DVT after treatment ends can reach up to 10% during the first year following deep vein thrombosis.


Standard treatment for venous thromboembolism is commonly with intravenous or subcutaneous heparin injections initially and overlapping with vitamin K antagonist such as warfarin or Coumadin.


Rivaroxaban is an oral agent which is a direct factor Xa inhibitor . Rivaroxaban is effective in the prevention of venous thromboembolism and it has shown to be effective after surgery.  A recent study was done to see if it is efficacious in treating venous thrombosis in general.  The study was published in the New England Journal of Medicine, volume 363, pages 2499 – 2510 by the EINSTEIN investigators.  The study showed that “rivaroxaban alone is as effective as standard therapy, with similar safety, for the treatment of acute DVT and that when treatment is continued, rivaroxaban is very effective  in preventing recurrences, as compared with placebo, and has an acceptable risk of bleeding”.


oral rivaroxaban, at a dose of 15 mg twice daily for the first 3 weeks, followed

by 20 mg once daily thereafter, without the need for laboratory monitoring, may provide an effective, safe, single-drug approach to the initial and continued treatment of venous thrombosis.


For treatment of DVT contact your hematologist or Dr. Karamanoukian at the Vein Treatment Center with offices in Buffalo Niagara.  You can contact him via or or call 716-839-3638. and are partners with



© 2012 Vein Guide, Inc. All rights reserved.